Researchers target ocular drug delivery market

Researchers target ocular drug delivery market


Researchers have developed a drug delivery device which attaches to the eye and could negate the need for repeat injections. The team from the University of Southern California has created a simple polymer device which is inserted under the conjunctiva and delivers a therapeutic to the affected area.


In time the device could come to replace the intravitreal injections which patients suffering from glaucoma and related eye diseases currently have to be administered with. 

Ellis Meng, researcher on the project, was keen to emphasise further refinements are in the pipeline. She said: "This prototype isn't optimally sized; it's our first go at proving the concept. We're now building a next-generation device." 

The one centimetre long prototype consists of a refillable reservoir sutured to the sclera which contains the therapeutic. Leading off this is a flexible tube which is inserted into the side of the eye and through which the drug is delivered.

Comments

Popular posts from this blog

 Role of Blockchain in Healthcare Data Management

Demystifying AI in Drug Discovery: Transforming Pharma R&D